This site is intended for Healthcare Professionals outside the US

JAKAVI demonstrated comprehensive haematologic control1,2

Significantly more patients receiving JAKAVI achieved complete haematologic remission (CHR) compared with those in the BAT arm1,2

  • JAKAVI enabled more than twice as many patients to achieve CHR1,2

CHR at Week 321-3

JAKAVI enabled more than twice as many Polycythemia Vera patients to achieve complete haematologic remission (CHR)

CHR was defined as having achieved all of the following: haematocrit control, platelet count ≤400 x 109/L, and leukocyte count ≤10 x 109/L.1

  • CHR was a key secondary endpoint1

88.5% of patients who achieved CHR at Week 32 maintained CHR at Week 484
Durability of CHR at Week 48 was a secondary endpoint3

JAKAVI helped control multiple key blood counts1-3

Control rates of key haematologic parameters at Week 321-3

JAKAVI, a JAK2 inhibitor, helped control multiple key blood counts in Polycythemia Vera patients

Haematocrit control was defined as the absence of phlebotomy eligibility, with no more than one post-randomisation phlebotomy allowed prior to Week 8. Phlebotomy eligibility was defined as haematocrit >45% and ≥3% higher than baseline or >48%, whichever was lower.1,2 Leukocyte control and platelet control as components of CHR were defined as ≤10 x 109/L and ≤400 x 109/L, respectively.1

  • The measures shown are the individual components of CHR, which was a key secondary endpoint1

Next: QoL improvements seen with JAKAVI treatment

BAT=best available therapy.

References:

  1. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435.
  2. JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; April 2015.
  3. Data on file. Novartis Pharma AG. Basel, Switzerland.
  4. Vannucchi AM, Kiladjian J-J, Griesshammer M, et al. Ruxolitinib proves superior to best available therapy in a prospective, randomized, phase 3 study (RESPONSE) in patients with polycythemia vera resistant to or intolerant of hydroxyurea. Paper presented at: 19th Congress of EHA; June 12-15, 2014; Milan, Italy.